Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of the Delta variant on vaccine efficacy and response strategies
Lianlian Bian, Qiushuang Gao, Fan Gao, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 10, pp. 1201-1209
Open Access | Times Cited: 215

Showing 1-25 of 215 citing articles:

The Lancet Commission on lessons for the future from the COVID-19 pandemic
Jeffrey D. Sachs, Salim S. Abdool Karim, Lara B. Aknin, et al.
The Lancet (2022) Vol. 400, Iss. 10359, pp. 1224-1280
Open Access | Times Cited: 539
Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein
Suresh Kumar, Thiviya S. Thambiraja, Kalimuthu Karuppanan, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1641-1649
Open Access | Times Cited: 515
A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
Srijan Chatterjee, Manojit Bhattacharya, Sagnik Nag, et al.
Viruses (2023) Vol. 15, Iss. 1, pp. 167-167
Open Access | Times Cited: 190
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines
Suresh Thakur, Shalitha Sasi, Sindhu Gopinathan Pillai, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 133
Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Daniel W. Kneller, Hui Li, G.N. Phillips, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 96
Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
Manish Dhawan, Abhilasha Sharma, Priyanka Choudhary, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 87
Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2
Negar Firouzabadi, Parisa Ghasemiyeh, Fatemeh Moradishooli, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109968-109968
Open Access | Times Cited: 74
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Vivek P. Chavda, Rajashri Bezbaruah, Kangkan Deka, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1926-1926
Open Access | Times Cited: 71
Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein
Suresh Kumar, Thiviya S. Thambiraja, Kalimuthu Karuppanan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 92
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
Jialing Yin, Chengcheng Li, Chunhong Ye, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 824-837
Open Access | Times Cited: 64
Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2
Joseph Newman, Nazia Thakur, Thomas P. Peacock, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1180-1188
Open Access | Times Cited: 64
The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines
Bruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes dos Santos Fonseca, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 591-591
Open Access | Times Cited: 62
Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma, et al.
International Journal of Biological Macromolecules (2022) Vol. 219, pp. 980-997
Open Access | Times Cited: 52
Correlation between Population Density and COVID-19 Cases during the Third Wave in Malaysia: Effect of the Delta Variant
Nuur Hafizah Md Iderus, Sarbhan Singh, Sumarni Mohd Ghazali, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 12, pp. 7439-7439
Open Access | Times Cited: 40
A multi-strain epidemic model for COVID-19 with infected and asymptomatic cases: Application to French data
Mathilde Massard, Raluca Eftimie, Antoine Perasso, et al.
Journal of Theoretical Biology (2022) Vol. 545, pp. 111117-111117
Open Access | Times Cited: 38
Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management
Vivek P. Chavda, Pankti C. Balar, Dixa A. Vaghela, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 160-160
Open Access | Times Cited: 28
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine
Ehsan Mostafavi, Sana Eybpoosh, Mohammad Karamouzian, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310302-e2310302
Open Access | Times Cited: 21
Severity, Pathogenicity and Transmissibility of Delta and Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention of COVID-19
Mehrnoosh Moghaddar, Ramtin Radman, Ian Macreadie
Microorganisms (2021) Vol. 9, Iss. 10, pp. 2167-2167
Open Access | Times Cited: 43
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González, et al.
Vaccine (2022) Vol. 40, Iss. 31, pp. 4220-4230
Open Access | Times Cited: 34
Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program
Chirayu Goswami, Michael Sheldon, Christian Bixby, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 29
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Armina Alagheband Bahrami, Ali Azargoonjahromi, Samin Sadraei, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 27
Emergence of COVID-19 Variants: An Update
Parakriti Gupta, Varsha Gupta, Chander Mohan Singh, et al.
Cureus (2023)
Open Access | Times Cited: 17
CCHFV vaccine development, current challenges, limitations, and future directions
Büşra Ahata, Günseli Bayram Akçapınar
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Discovery of a 2′-α-Fluoro-2′-β-C-(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent
Lan Liang, Yonggang Meng, Xiaoyu Chang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies
Fatimah S. Alhamlan, Ahmed A. Al‐Qahtani
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1263-1263
Open Access
Page 1 - Next Page

Scroll to top